Multiple Sulfatase Deficiency (MSD) Cell Models for Research

Multiple Sulfatase Deficiency (MSD) is an ultra-rare autosomal recessive lysosomal storage disorder caused by mutations in the SUMF1 gene, which encodes the formylglycine-generating enzyme (FGE) essential for the post-translational activation of all cellular sulfatases. The exact incidence is unknown but estimated at <1 in 1,000,000 live births (WHO, 2023). Clinical presentation varies from severe neonatal to mild late-onset forms, with symptoms including ichthyosis, skeletal deformities, neurological deterioration, and developmental delay. Prognosis is poor; severe cases often result in death in early childhood, while milder forms may allow survival into adulthood. The disease burden is significant for affected families and healthcare systems due to the need for multidisciplinary care. Research on MSD is crucial for understanding sulfatase biology and developing therapies, as there is currently no cure.

MSD is an ideal model for studying the role of sulfatases in various physiological processes, including development, metabolism, and cellular homeostasis. The disease is monogenic, making it amenable to gene editing. Public datasets, such as those from the Rare Diseases Clinical Research Network, provide clinical and genetic data. Open questions include the genotype-phenotype correlation, the molecular basis of tissue-specific symptoms, and the potential for enzyme replacement or gene therapy. Gene-edited cell models allow researchers to dissect the impact of specific SUMF1 mutations on sulfatase activity and downstream pathways, facilitating drug discovery.

MSD is caused by deficient activity of all sulfatases due to mutations in SUMF1. The key pathways affected include:

1. Lysosomal degradation: Sulfatases are required for the breakdown of glycosaminoglycans, sulfolipids, and sulfated steroids. Deficiency leads to accumulation of these substrates in lysosomes, causing cellular dysfunction.

2. Sulfation signaling: Sulfatases modulate the sulfation status of molecules such as heparan sulfate, which affects growth factor signaling (e.g., FGF, Wnt) and cell adhesion.

3. Endoplasmic reticulum (ER) stress: Mutant FGE may misfold and accumulate in the ER, triggering the unfolded protein response (UPR) and apoptosis.

4. Inflammation: Substrate accumulation can activate microglia and macrophages, leading to neuroinflammation and neurodegeneration.

Data from ClinVar and literature. The most common mutations include c.739G>A (p.Gly247Arg) and c.1045C>T (p.Arg349Trp), which affect FGE stability or catalytic activity.

The deficiency of sulfatases impacts multiple signaling networks:

• • Wnt signaling: Heparan sulfate proteoglycans (HSPGs) are sulfated; altered sulfation affects Wnt ligand binding and signaling, leading to developmental defects.
• • FGF signaling: Similar to Wnt, FGF signaling is modulated by HSPGs; abnormal sulfation impairs FGF-mediated cell proliferation and differentiation.
• • PI3K/AKT pathway: Substrate accumulation may activate stress pathways, including PI3K/AKT, promoting cell survival or apoptosis depending on context.
• • Inflammatory signaling: Activation of Toll-like receptors (TLRs) by accumulated substrates triggers NF-κB and pro-inflammatory cytokine production.

Organoids derived from patient iPSCs can recapitulate tissue-specific phenotypes, such as neuronal and skin defects, providing a more physiologically relevant model.

• • Sumf1 knockout mouse: Recapitulates MSD phenotypes, including growth retardation, skeletal abnormalities, and neurological deficits.
• • Zebrafish models: Used for developmental studies and drug screening.
• • Patient-derived xenografts (PDX): Not commonly used for MSD as it is not a cancer, but may be used for testing therapies in immune-deficient mice.
• • Induced models: Treatment with sulfatase inhibitors can mimic partial deficiency in cell lines.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific SUMF1 mutations, providing precise models to study genotype-phenotype relationships. For example, a SUMF1 knockout cell line can be generated by introducing a frameshift mutation, while a knock-in line can carry a patient-specific missense mutation. These models are commercially available from various sources and are sequence-verified to ensure accuracy. They are invaluable for drug screening, functional studies, and validation of therapeutic targets.

Knockout and knock-in lines allow researchers to validate the function of SUMF1 and other genes involved in sulfatase activation. For example, a SUMF1 knockout line can be used to identify downstream substrates and pathways affected by loss of sulfatase activity. Knock-in lines with specific mutations can help determine the impact of each mutation on FGE function and sulfatase activity.

Isogenic pairs (wild-type vs. mutant) are ideal for high-throughput screening of compounds that can rescue sulfatase activity or reduce substrate accumulation. They can also be used to study resistance mechanisms to potential therapies, such as enzyme replacement or pharmacological chaperones.

CRISPR-based synthetic lethality screens can identify genes that, when knocked out, are lethal only in the context of SUMF1 deficiency. These genes may serve as novel therapeutic targets. Additionally, gene-edited cells can be used to discover biomarkers for disease progression and treatment response.